Fluticasone propionate
[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-Difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
Drag to rotate. Structure from PubChem CID 444036.
Background
Listing
- Schedules
- Schedule 2 to 4, conditions apply
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
7 registered products listed
Counted through the register's ingredient index, which does not reach every record.
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Fluticasone propionate | Cutivate, Flixotide accuhaler, Flixotide cfc-free, +9 more | cream, 50, 100, 125, +3 more | 5 applicants | 22 registrations | S2 to S4conditions apply |
| Salmeterol | Serevent accuhaler, Serevent cfc-free | 25 μg | Glaxosmithkline South Africa (Pty) Limited | 2 registrations | S4 |
| Fluticasone propionate, salmeterol | Seretide accuhaler, Seretide, Sereflo hfa, +6 more | 25/50, 25/125, 25/250, 50/100, +3 more | 4 applicants | 19 registrations | S4 |
| Fluticasone, salmeterol | Foxair, Salmeterol xinafoate fluticasone propionate cipla, Sereflo dpi | 25/50, 25/125, 25/250, + 50/100, +3 more | 2 applicants | 7 registrations | S4 |
| Fluticasone propionate, salmeterol xinafoate | Adeflo | 50, 125, 250 | Glenmark Pharmaceuticals South Africa (Pty) Ltd | 3 registrations | S2 to S4conditions apply |
| Azelastine, fluticasone propionate | Dymista nasal, Cipzamist | 1,0 mg and 0,365 mg, 137 μg & 50 μg | 2 applicants | 2 registrations | S2 |
| Fluticasone propionate, formoterol | Tizaglenn co | 12 ug/250 ug | Glenmark Pharmaceuticals South Africa (Pty) Ltd | 570339 | S2 to S4conditions apply |
Regulatory status
Where S2 to S4 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 2: a pharmacist can sell it directly, without a prescription. At the most restrictive, Schedule 4: prescription-only medicine. The listings below say which applies to which form, strength or pack size.
Schedule S2 to S4, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Fluticasone propionate
S4: Fluticasone propionate
- except when intended for nasal administration as an aqueous spray, in the short-term (less than 6 months prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 100 micrograms per nostril; and (ii) a maximum pack size of 120 doses. (S2)
- except when intended for inhalation or nasal administration. (S3)
Consolidated Schedules 06 July 2026, lines 6423 to 6433
S3: Fluticasone propionate
- when intended for inhalation or nasal administration;
- except when intended for nasal administration as an aqueous spray in the short-term (less than 6 months prophylaxis and treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 100 micrograms per nostril; and (ii) a maximum pack size of 120 doses. (S2)
- except when intended for administration other than by inhalation or nasal administration. (S4)
Consolidated Schedules 06 July 2026, lines 3641 to 3653
S2: Fluticasone propionate
- when intended for nasal administration, as an aqueous spray, in the short-term (less than 6 months) prophylaxis and treatment of symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12 years of age, subject to- (i) a maximum daily dose of 100 micrograms per nostril; (ii) and a maximum pack size limit of 120 doses; (S3)
- except when intended for administration other than by inhalation or nasal administration. (S4)
Consolidated Schedules 06 July 2026, lines 2042 to 2052
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.